Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Chinese Patent Office
Express Scripts

Generated: August 23, 2019

DrugPatentWatch Database Preview

Litigation Details for MERCK SHARP & DOHME CORP. v. SANDOZ INC. (D.N.J. 2012)

  Try a free trial

See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in MERCK SHARP & DOHME CORP. v. SANDOZ INC.
The small molecule drug covered by the patent cited in this case is   Try a Free Trial .

Details for MERCK SHARP & DOHME CORP. v. SANDOZ INC. (D.N.J. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-05-31 1 Complaint Merck owns United States Patent No. 5,691,336 (“the ’336 patent”), which was duly and legally … INFRINGEMENT BY SANDOZ OF U.S. PATENT NO. 5,691,336 15. Plaintiff re-alleges…expiration of the ’336 patent including its patent term extension, would infringe the ’336 patent under 35 U.S.C… ’336 patent is attached as Exhibit A. 11. Merck owns United States Patent No. 5,716,942…’336 patent, and that it sought approval of its ANDA prior to the expiration of the ’336 patent. External link to document
2014-04-16 150 would not infringe U.S. Patent No. 5,691,336 (“the ’336 patent”), the patent covering the fosaprepitant…Sandoz alleged that Merck’s ’336 patent admitted that a Merck foreign patent application, WO’679, was prior…product claimed in the ’336 patent before its expiration including its patent term extension, Sandoz …product similarly infringed U.S. Patent No. 5,716,942 (“the ’942 patent”). 1 The Court conducted an …infringe the ’336 patent. On June 25, 2013, however, Accord withdrew its Local Patent Rule Invalidity External link to document
2015-08-27 287 Claims”) in U.S. Patent No. 5,691,336 (“the ’336 patent”) for obviousness. The ‘336 patent was issued to…undisputed that the patent examiner allowed the ’336 patent to issue as a patent, even though WO ’679… 169. The related patent, U.S. Patent No. 4,443,440 (“the Anderson ’440 patent”) (PTX- 60), described…non-obviousness, of the ‘336 patent, the burden of proof in this matter rests on Sandoz. Patents are presumed to… specifically claimed in the ’336 patent, which is the patent-in-suit for trial in this litigation. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.